B-20 study of Oncotype DX Breast Recurrence Score test shows who to treat for breast cancer.- Genomic Health.

Genomic Health announced the publication of positive results from a new analysis of the NSABP-led B-20 study reconfirming that the Oncotype DX Breast Recurrence Score test predicts which patients with early-stage, HER2-negative breast cancer will benefit from chemotherapy. Applying the patient criteria from the TAILORx study, the largest ever breast cancer treatment trial, sponsored by the National Cancer Institute (NCI), and led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), NSABP conducted a new analysis in 569 patients from its previously completed B-20 study. The results show that Oncotype DX provides definitive information about which patients will derive life-saving benefit from chemotherapy treatment. The new results, published in November in the Nature Partner Journals (NPJ) Breast Cancer, show a statistically significant (p<0.001) benefit from the addition of chemotherapy to hormonal therapy in patients with breast recurrence score results greater than 25. about 50 percent of all breast cancer patients diagnosed worldwide each year have hormone-receptor positive her2-negative node-negative cancer. the tailorx study published in the new england journal of medicine established that chemotherapy may be spared in the majority of these patients.>

Comment: Importantly, some early-stage breast cancer patients � as reinforced by the new NSABP publication - will derive life-saving benefit from chemotherapy, including women with Breast Recurrence Score results of 26 to 100. TAILORx participants with Breast Recurrence Score results from 26 to 100 were treated with chemotherapy plus endocrine therapy.